Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-DA-EPOCH vs R-CEOP90 in High-risk DLBCL
NCT03213977Phase 3Active, not recruiting
- Sponsor
- Fujian Medical University
- Start
- Jul 2017
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin + cyclophosphamide + vincristine + prednisone + rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Fujian Medical University. Started Jul 2017; status: active, not recruiting.
02
Drugs
epirubicin + cyclophosphamide + vincristine + prednisone + rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03213977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03213977.